Adicet Bio, Inc’s Post

Our latest content on eupolicy.bms.com is about #cell therapy - a revolution in #healthcare #innovation. With #CAR-T cell therapy, a patient’s own T-cells are genetically engineered to recognize and eliminate specific cancer cells. Administered as a one-time infusion, #CAR-T cell therapy could be a game changer for eligible cancer patients. It replaces a lifetime of treatment. For cell therapy, the challenges are to scale manufacturing, adapt the supply chain, update and align regulatory pathways, and agree on a payment model that is sustainable for healthcare systems and rewards innovation. Dialogue between all stakeholders - especially, industry, clinical, patient and policy leaders - could help to overcome these challenges. More in an interview here https://bit.ly/3R6VHUo with @Anne Kerber, SVP, Head of Late Clinical Development at @Bristol Myers Squibb. #BMS_Employee #FutureProofingMedicines

📢Groundbreaking FDA Approval: Solid Tumor Cell Therapy! 📰 Sorry, the page you requested cannot be found. Please go back to the home page. 🏠 #BioprocessUpdates #Iovance #FDAapproval #solidtumortherapy #medicalnews #healthcare #cancertreatment #celltherapy #innovation #oncology #medicalbreakthrough #science #research #healthnews #biotechnology #medicaladvancement ▷ Read the full article here: 📎 https://lnkd.in/eRyZiyJJ

📰 Are more rapid sterility testing methods needed? According to a group of researchers at SCTbio, the answer is yes. In this week's #cellandgene newsletter, we learn more about a neglected area of #CAR-T optimization. We also explore AstraZeneca's recent $300 million facility investment in Maryland. And, research from California State University, Los Angeles - College of Professional and Global Education that has identified Tyrosinase Related Protein 1 as a CAR-T cell therapy target to treat patients with cutaneous and rare melanoma subtypes. 🔎 Not subscribed to our newsletter yet? Sign up here: https://bit.ly/3SCDpKo

Labcorp’s disseminated NALM6-Luc-mCh-Puro ALL model in NSG mice, established by our teams in house, provides yet another tool for the preclinical development of therapies directed against B-cell malignancies. We have characterized the response to CD19-targeted CAR T cell treatment and evaluated the activity and persistence using flow cytometry with expanded Persistence T panels. Find out more: https://lnkd.in/epkPH6CJ #AcuteLymphoblasticLeukemia #TumorModel #FlowCytometry

Our latest content on eupolicy.bms.com is about #cell therapy - a revolution in healthcare #innovation.  With CAR-T cell therapy, a patient’s own T-cells are genetically engineered to recognize and eliminate specific #cancer cells. Administered as a one-time infusion, CAR-T cell therapy could be a game-changer for eligible cancer #patients. It replaces a lifetime of treatment. For cell therapy, the challenges are to scale manufacturing, adapt the supply chain, update and align regulatory pathways, and agree on a payment model that is sustainable for healthcare systems and rewards innovation. Dialogue between all stakeholders - especially, industry, clinical, patient and policy leaders - could help to overcome these challenges. More in an interview here https://bit.ly/3R6VHUo with Anne Kerber, SVP, Head of Late Clinical Development at Bristol Myers Squibb. #BMS_Employee #FutureProofingMedicines 

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated #SEC document on Monday morning... ...Artiva’s planned IPO arrives at a moment of flux for the biotech industry. Private biotechs just reeled in the most amount of capital in a quarter since early 2022, but “the IPO market remains the lone holdout with deal volume trailing expectations as aftermarket performance remains a significant issue,” Raymond James bankers wrote in a biweekly industry update on Sunday.... #offtheshelf #allogeneic #celltherapies #celltherapy #advancedtheraies #regenerativemedicine #IPO #publicmarkets #funding #financing #Phase1 #clinicaltrials #biotech #biotechnology #lifescience #lifesciences #lupus #Bcellmalignancies #solidtumors #bloodcancers #systemiclupuserythematosus #hematology #oncology #cancer #IPOmarket #pipeline #NKcelltherapy

Labcorp’s disseminated NALM6-Luc-mCh-Puro ALL model in NSG mice, established by our teams in house, provides yet another tool for the preclinical development of therapies directed against B-cell malignancies. We have characterized the response to CD19-targeted CAR T cell treatment and evaluated the activity and persistence using flow cytometry with expanded Persistence T panels. Find out more: https://lnkd.in/gFfvt7xx #AcuteLymphoblasticLeukemia #TumorModel #FlowCytometry

ConcertAI and Caris Life Sciences Sign a Collaboration Agreement with AbbVie to Enhance Research and Development Efforts Towards Cancer Treatment #concertai #carislifesciences #abbvie #pharma #cancer #oncology #artificialintelligence #machinelearning #ai #ml #clinicaltrial #database #precisionmedicine #researchanddevelopment #realworld #cancerindications #patientenrollment

Labcorp’s disseminated NALM6-Luc-mCh-Puro ALL model in NSG mice, established by our teams in house, provides yet another tool for the preclinical development of therapies directed against B-cell malignancies. We have characterized the response to CD19-targeted CAR T cell treatment and evaluated the activity and persistence using flow cytometry with expanded Persistence T panels. Find out more: https://lnkd.in/gigwP7M4 #AcuteLymphoblasticLeukemia #TumorModel #FlowCytometry